<DOC>
	<DOC>NCT01018511</DOC>
	<brief_summary>Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.</brief_summary>
	<brief_title>Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Voiding and storage symptoms diagnosed as LUTS associated with BPH for ≥ 3 months A total International Prostate Symptom Score (IPSS) of ≥13 A maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with voided volume of ≥120 mL during free flow A micturition frequency of ≥8 and at least 2 episodes of urgency with Patient Perception of the Intensity of Urgency Scale grade 3 or 4 per day on average on the 3 day micturition diary (at randomization) Any significant Post Void Residual volume (&gt;150 mL) A prostate with estimated weight ≥75 ml as assessed by transvesical or transrectal ultrasound Evidence of a symptomatic urinary tract infection</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EC905</keyword>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Tamsulosin hydrochloride OCAS</keyword>
	<keyword>Treatment</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Vesomni</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
</DOC>